# A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions

> **NCT07734064** · PHASE1 · RECRUITING · sponsor: **Astellas Institute for Regenerative Medicine** · enrollment: 30 (estimated)

## Conditions studied

- Stargardt Disease
- Stargardt Macular Dystrophy
- Stargardt-like Macular Dystrophy

## Interventions

- **DRUG:** ASP2020

## Key facts

- **NCT ID:** NCT07734064
- **Lead sponsor:** Astellas Institute for Regenerative Medicine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-10
- **Primary completion:** 2029-09-30
- **Final completion:** 2029-09-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07734064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07734064, "A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07734064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*